Abbvie has acquired only one company in 2010 with the purchase of Facet Biotechnology valued at $722 million.
This acquisition exploits Facet’s promising biologics technology intended to treat multiple sclerosis and complements Abbvie’s diverse oncology program.
Very recently in June 2014, Abbvie expressed interest in purchasing Shire but the proposal was rejected after several rounds of meeting.
Our report provides more detailed insight into the details of each deal. See: Report: Partnering Agreements with Abbvie 2009-2014
Full details on each deal can be found at Current Agreements (subscription required)
Available reports from Current Partnering
Report: Partnering Agreements with Abbvie 2009-2014
Available resources for deal coverage for Abbvie
Read: more on Abbvie company profile, recent partnering, M&A and financing news and articles
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk